Opko Health, Inc. Sells 50,000 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

Posted by Andrew Walz on Aug 3rd, 2024

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) major shareholder Opko Health, Inc. sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $33.86, for a total transaction of $1,693,000.00. Following the completion of the sale, the insider now owns 3,073,403 shares in the company, valued at $104,065,425.58. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Opko Health, Inc. also recently made the following trade(s):

On Wednesday, July 31st, Opko Health, Inc. sold 88,839 shares of GeneDx stock. The shares were sold at an average price of $33.50, for a total transaction of $2,976,106.50.
On Friday, July 26th, Opko Health, Inc. sold 60,000 shares of GeneDx stock. The shares were sold at an average price of $33.85, for a total transaction of $2,031,000.00.
On Wednesday, July 24th, Opko Health, Inc. sold 75,000 shares of GeneDx stock. The shares were sold at an average price of $33.72, for a total transaction of $2,529,000.00.
On Monday, July 22nd, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $32.61, for a total transaction of $1,630,500.00.
On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.29, for a total transaction of $807,250.00.
On Wednesday, July 17th, Opko Health, Inc. sold 25,000 shares of GeneDx stock. The stock was sold at an average price of $32.93, for a total transaction of $823,250.00.
On Friday, July 5th, Opko Health, Inc. sold 36,118 shares of GeneDx stock. The stock was sold at an average price of $28.24, for a total transaction of $1,019,972.32.
On Wednesday, July 3rd, Opko Health, Inc. sold 14,082 shares of GeneDx stock. The stock was sold at an average price of $28.23, for a total transaction of $397,534.86.
On Monday, July 1st, Opko Health, Inc. sold 50,000 shares of GeneDx stock. The stock was sold at an average price of $26.63, for a total transaction of $1,331,500.00.

GeneDx Stock Performance

NASDAQ:WGS opened at $30.07 on Friday. The company has a fifty day moving average of $28.43 and a 200-day moving average of $16.51. The firm has a market capitalization of $785.43 million, a P/E ratio of -5.81 and a beta of 2.29. The company has a quick ratio of 2.99, a current ratio of 3.22 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $1.16 and a twelve month high of $35.65.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of recent analyst reports. Craig Hallum boosted their price target on shares of GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday. BTIG Research boosted their price target on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen boosted their price target on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Financial Group initiated coverage on shares of GeneDx in a research report on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target on the stock. Finally, The Goldman Sachs Group boosted their price target on shares of GeneDx from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.80.

Read Our Latest Stock Analysis on WGS

Institutional Trading of GeneDx

Several hedge funds have recently modified their holdings of the stock. Thompson Davis & CO. Inc. increased its stake in GeneDx by 99.4% during the 4th quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock valued at $55,000 after purchasing an additional 9,944 shares in the last quarter. Decheng Capital LLC bought a new stake in GeneDx during the 4th quarter valued at $285,000. PFG Investments LLC bought a new stake in GeneDx during the 1st quarter valued at $95,000. Vanguard Group Inc. increased its stake in GeneDx by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after purchasing an additional 28,678 shares in the last quarter. Finally, Gagnon Advisors LLC increased its stake in GeneDx by 41.6% during the 1st quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after purchasing an additional 62,059 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

About GeneDx

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.